| Sernova Corp. |
|
Sernova Corp. (TSX-V:SVA) is a biotechnology research and development company focused on commercializing innovative medical technologies. The Company's current mission is to cure insulin dependent diabetes through its insulin replacement cellular therapy, Sertolin. Diabetes affects 2 million people in Canada and over 20 million people in North America. Worldwide, 150 million people currently suffer from diabetes, and by year 2025, over 300 million people are expected to have the disorder. Diabetes often leads to serious medical complications including blindness, amputation, heart disease, stroke and kidney disease. Sernova's lead product, Sertolin, replaces the insulin producing cells no longer functioning in a diabetic. By co-transplanting two types of porcine cells into a small medical device, Sernova is focused on solving the donor supply issue and elminating the need for anti-rejection drugs. contact: Justin Leushner T: 519.639.7867 website: www.sernova.com |
